News Archive
Implandata’s Breakthrough EYEMATE-SC Biosensor for Remote Glaucoma Care is CE Marked
Implandata Ophthalmic Products, a digital health company with offices in Germany and San Diego, California has announced today that its EYEMATE-SC biosensor has obtained CE Mark. This device is used in conjunction with the breakthrough EYEMATE system for digitally enabled remote glaucoma monitoring and management.
Read more … Implandata’s Breakthrough EYEMATE-SC Biosensor for Remote Glaucoma Care is CE Marked
Labforward ramps up Series B financing to >€8.5 million in second closing
With the successful completion of a second closing, Labforward adds >€3m to the Series B from January, bringing the total funds raised to >€8.5m. The majority of the new investment comes from the Fielmann Family Office.
Read more … Labforward ramps up Series B financing to >€8.5 million in second closing
Implandata’s EYEMATE System Obtains FDA Breakthrough Device Designation
Implandata Ophthalmic Products, a digital health company with offices in Germany and San Diego, California has announced today that its game-changing EYEMATE system for digitally enabled remote patient monitoring and management of glaucoma has obtained Breakthrough Device Designation (BDD) from the U.S. Food and Drug Administration (FDA).
Read more … Implandata’s EYEMATE System Obtains FDA Breakthrough Device Designation
Implandata’s EYEMATE System Protects Glaucoma Patients – Even During Lockdown
People with glaucoma and eye doctors face a dilemma. On one hand, patients with glaucoma are at high risk of losing their eyesight if their disease progresses undetected and essential therapy adjustments are delayed. On the other hand, these typically elderly, vulnerable individuals are often hampered in seeing their doctor for office visits, particularly during a lockdown.
Read more … Implandata’s EYEMATE System Protects Glaucoma Patients – Even During Lockdown
CEVEC announces new license agreement for its AAV manufacturing technology ELEVECTA® in gene therapy
CEVEC Pharmaceuticals GmbH (CEVEC) today announced the signing of a license agreement with Biogen Inc. (Biogen; Nasdaq: BIIB) for the use of CEVEC’s proprietary ELEVECTA® Technology for the manufacturing of adeno‐associated virus (AAV) vectors for gene therapy applications.
Miracor Medical raises 24M€
Funds will be used for clinical studies and initiation of commercialization
Permanent Link to Laboratory IT solution provider Labforward announces major rebranding at BCEIA in Beijing, China
At the Beijing Conference and Exhibition on Instrument Analysis (BCEIA), a leading Chinese trade fair for laboratory instruments, Labforward today announced a major rebranding to unify its products under a clear, clean identity. From today, the product cubuslab, an Internet-of-Things (IoT) platform for laboratory devices, will be known as Laboperator. The electronic lab notebook software (ELN) Labfolder will retain its original name.